Retracted: Immunotherapy of metastatic renal cell carcinoma
- 28 April 2009
- Vol. 115 (S10), 2298-2305
- https://doi.org/10.1002/cncr.24236
Abstract
Renal cell carcinoma (RCC) evokes an immune response, which occasionally has resulted in spontaneous and dramatic remissions. In an attempt to reproduce or accentuate this response, various immunotherapeutic strategies have been studied. The most consistent antitumor activity has been reported with interferon‒α (IFN‐α) and interleukin‐2 (IL‐2). In recent years, randomized trials have suggested that high‐dose, intravenous bolus IL‐2 is superior in terms of response rate and possibly in terms of response quality to regimens that involve either low‐dose IL‐2 and IFN‐α, intermediate‐ or low‐dose IL‐2 alone, or low‐dose IFN‐α alone. More significantly, investigations associated with those trials suggested that the potential exists for identifying predictors of response (or resistance) and limiting IL‐2 therapy to those patients who hare most likely to benefit. Although the role of low‐dose, single‐agent cytokines is limited, combinations of cytokines with targeted therapy may have merit. Several studies, including 2 completed, large, phase 3 trials of interferon plus bevacizumab versus interferon alone, have demonstrated superior efficacy with the combination regimen compared with cytokine monotherapy and suggested the potential of an additive effect that requires further exploration. For patients who are unlikely to benefit from IL‐2 or who are unable to receive it, the emergence “targeted immunotherapy” offers hope for improved clinical outcome. Improvements in patient selection, novel agents, and combination therapy will be required to optimize the benefits of immunotherapy in metastatic RCC as the list of effective therapies grows. Cancer 2009;115(10 suppl):2298‐305. © 2009 American Cancer Society.Keywords
Funding Information
- Genentech, Novartis Pharmaceuticals, Pfizer, Inc, and Wyeth Pharmaceuticals
- Dana-Farber/Harvard Cancer Center Renal Cancer Specialized Program of Research Excellence (CA101942/01)
- Genentech and Novartis
This publication has 50 references indexed in Scilit:
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Immunotherapy for metastatic renal cell carcinomaBJU International, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell CancerJournal of Clinical Oncology, 2006
- Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer PatientsCancer Research, 2006
- Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal CancerClinical Cancer Research, 2005
- Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinomaOncogene, 2004
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Advances in Allogeneic Stem Cell TransplantationThe Cancer Journal, 2002